Veralipride
Modify Date: 2024-01-11 18:57:19
Veralipride structure
|
Common Name | Veralipride | ||
|---|---|---|---|---|
| CAS Number | 66644-81-3 | Molecular Weight | 383.46300 | |
| Density | 1.23 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C17H25N3O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VeraliprideVeralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms. |
| Name | Veralipride |
|---|---|
| Synonym | More Synonyms |
| Description | Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms. |
|---|---|
| Related Catalog | |
| In Vitro | Veralipride administration (100 mg/day for 30 days) induces a significant reduction in vasomotor symptoms and is more effective than placebo. Treatment is followed by the expected increase in plasma prolactin levels and by a significant decrease in mean plasma LH. A significant reduction is observed in objectively recorded hot flushes after Veralipride treatment[1]. Veralipride is well absorbed when administered orally, achieving maximal concentrations at 2.5 hours. It is poorly metabolized and is eliminated in the urine and feces. After oral administration, the half-life is 4 hours, and 44% is excreted without any changes in urine in the first 120 hours[2]. A total of 57 adverse events are registered during the 386-month treatment. For the 20×10 dosing schedule, the highest incidence is observed for anxiety (2.2%), drowsiness, and weakness (1.5%); for the 5 × 2 dosing schedule, the highest incidence is observed for drowsiness (5.3%) and headache (2.6%)[3]. Veralipride is known to cause extrapiramidal signs such as bucco-facial or limb dyskinesia. Veralipride may cause reversible parkinsonism[4]. |
| References |
[2]. Carranza-Lira S, et al. Actual status of veralipride use. Clin Interv Aging. 2010 Sep 7;5:271-6. |
| Density | 1.23 g/cm3 |
|---|---|
| Molecular Formula | C17H25N3O5S |
| Molecular Weight | 383.46300 |
| Exact Mass | 383.15100 |
| PSA | 119.34000 |
| LogP | 2.84130 |
| Index of Refraction | 1.547 |
| Storage condition | 2-8℃ |
| HS Code | 2935009090 |
|---|
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
| 2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide |